Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL. It has collaboration agreements with Celgene Corporation, Genentech Inc., and Glaxo Group Limited, as well as with Roche Molecular Systems, Inc., Eisai Co. Ltd., and Lymphoma Study Association. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EPZM
CUSIPN/A
Phone617-229-5872
Debt
Debt-to-Equity RatioN/A
Current Ratio10.43
Quick Ratio10.43
Price-To-Earnings
Trailing P/E Ratio-6.22
Forward P/E Ratio-6.10
P/E GrowthN/A
Sales & Book Value
Annual Sales$10 million
Price / Sales94.16
Cash FlowN/A
Price / CashN/A
Book Value$3.40 per share
Price / Book3.99
Profitability
EPS (Most Recent Fiscal Year)($2.18)
Net Income$-134,300,000.00
Net MarginsN/A
Return on Equity-61.42%
Return on Assets-50.53%
Miscellaneous
Employees131
Outstanding Shares69,490,000
Market Cap$941.56
Epizyme (NASDAQ:EPZM) Frequently Asked Questions
What is Epizyme's stock symbol?
Epizyme trades on the NASDAQ under the ticker symbol "EPZM."
How were Epizyme's earnings last quarter?
Epizyme Inc (NASDAQ:EPZM) posted its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.05. During the same quarter last year, the business earned ($0.56) earnings per share. View Epizyme's Earnings History.
When is Epizyme's next earnings date?
What price target have analysts set for EPZM?
10 Wall Street analysts have issued twelve-month price targets for Epizyme's shares. Their predictions range from $16.00 to $26.00. On average, they expect Epizyme's stock price to reach $23.10 in the next year. This suggests a possible upside of 70.5% from the stock's current price. View Analyst Ratings for Epizyme.
What is the consensus analysts' recommendation for Epizyme?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Epizyme stock?
Here are some recent quotes from research analysts about Epizyme stock:
- 1. According to Zacks Investment Research, "Epizyme's efforts on developing its lead candidate, tazemetostat, for a number of hematological malignancies and genetically defined solid tumors are impressive. The company is assessing its timeline for submitting a new drug application to the FDA for tazemetostat regarding follicular lymphoma. The company plans to file a first new drug application for tazemetostat with respect to epithelioid sarcoma in the fourth quarter of 2018. A potential approval for the candidate will be a significant boost to the company. Loss estimates have narrowed ahead of the company’s Q2 earnings release. Epizyme has a positive record of earnings surprises in recent quarters. Shares of the company have outperformed the industry in the year so far. However, the company is highly dependent on its collaboration partners for the development of its candidates." (7/19/2018)
- 2. HC Wainwright analysts commented, "Valuation and risks. Our price target of $25 on Epizyme is based on a probability-adjusted sum-of-parts NPV-DCF: $21 EZH2 (NHL + INI-) + $1 DOT1L (MLL-R) + $3 cash. Risks to our investment thesis and target price include: (1) failure in clinical trials; (2) failure to secure regulatory approvals; and (3) a smaller- than-anticipated commercial opportunity due to market sizing, competition, and pricing. Epizyme, Inc." (6/27/2018)
- 3. Cann analysts commented, "Epizyme presented two posters at the American Society of Hematology Meeting on December 10-11, 2017. These included a biomarker study in non-Hodgkin’s lymphoma (NHL) and preliminary response data from the diffuse large B cell lymphoma (DLBCL) cohort from the ongoing phase II study of tazemetostat in NHL. The data presented is very supportive of our outlook." (12/12/2017)
Who are some of Epizyme's key competitors?
Some companies that are related to Epizyme include Array Biopharma (ARRY), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), Amicus Therapeutics (FOLD), The Medicines (MDCO), Horizon Pharma (HZNP), Supernus Pharmaceuticals (SUPN), Intercept Pharmaceuticals (ICPT), Blueprint Medicines (BPMC), Evotec (EVTCY), Emergent Biosolutions (EBS), Heron Therapeutics (HRTX), Portola Pharmaceuticals (PTLA) and Endo International (ENDP).
Who are Epizyme's key executives?
Epizyme's management team includes the folowing people:
- Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 50)
- Mr. Matthew E. Ros, Chief Operating Officer (Age 51)
- Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory Board
- Dr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory Board
- Dr. Michael Boretti, VP of Bus. Devel.
Has Epizyme been receiving favorable news coverage?
News coverage about EPZM stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Epizyme earned a coverage optimism score of 0.24 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 47.11 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are Epizyme's major shareholders?
Epizyme's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.65%) and Fox Run Management L.L.C. (0.05%). Company insiders that own Epizyme stock include Andrew E Singer, David M Mott, Matthew Ros, Peter Tai-Ching Ho and Robert A Copeland. View Institutional Ownership Trends for Epizyme.
Which institutional investors are selling Epizyme stock?
EPZM stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. Company insiders that have sold Epizyme company stock in the last year include Matthew Ros and Peter Tai-Ching Ho. View Insider Buying and Selling for Epizyme.
Which institutional investors are buying Epizyme stock?
How do I buy shares of Epizyme?
Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Epizyme's stock price today?
One share of EPZM stock can currently be purchased for approximately $13.55.
How big of a company is Epizyme?
Epizyme has a market capitalization of $941.56 million and generates $10 million in revenue each year. The biopharmaceutical company earns $-134,300,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis. Epizyme employs 131 workers across the globe.
How can I contact Epizyme?
Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]
MarketBeat Community Rating for Epizyme (NASDAQ EPZM)
MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote "Outperform" if you believe EPZM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days.
